Skip to main content

Advertisement

SpringerLink
Log in

Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Approximately 35% of PBC patients have progressive disease despite treatment with UDCA.

Aims

We offered treatment with methotrexate and colchicine to PBC patients who had not responded fully to UDCA, after at least 1 year of treatment.

Methods

A total of 91 PBC patients failed to respond adequately to UDCA, defined as patients whose liver biopsies showed persistent interface hepatitis and whose serum alkaline phosphatase levels remained more than 50% above normal after at least 12 months on UDCA. We added colchicine (0.6 mg orally twice daily) for 6 months. If there was no decrease in alkaline phosphatase, methotrexate (0.25 mg/kg lean body weight orally per week) was added. Liver biopsies were performed at least three times: at diagnosis, after a patient had been on UDCA for at least 1 year (mean 3.4 years), and after a patient had been on methotrexate for at least 6 months (mean 2.2 years). A fourth liver biopsy was performed in 51 patients after they had been on methotrexate for at least another year (mean 3.5 years).

Results

From the time that methotrexate was begun until the final visit, there were significant decreases in the mean levels of alkaline phosphatase, 323 to 151, ALT, 73 to 39, fibrosis, 2.5 to 2.0, and inflammation scores, 2.0 to 1.0, (p < 0.0001 for all). Based on pre-specified definitions, 73 patients (80%) responded to methotrexate while 18 (20%) did not.

Conclusions

In 91 PBC patients who responded incompletely to UDCA, colchicine and methotrexate significantly improved liver enzyme tests and liver histology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E. AASLD practice guidelines: primary Biliary Cirrhosis. Hepatology. 2009;50:291–308.

    Article  PubMed  Google Scholar 

  2. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systemic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analysis. Am J Gastroenterol. 2007;102:1799–1807.

    Article  CAS  PubMed  Google Scholar 

  3. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720.

    Article  PubMed  Google Scholar 

  4. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877.

    Google Scholar 

  5. Lee J, Belanger A, Friedman S, Bach N. Transplantation trends among primary biliary cirrhosis patients from 1995 to 2004. Hepatology. 2006;44:628A.

    Google Scholar 

  6. Kaplan M, Poupon R. Treatment with immunosupressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Hepatology. 2009;50:562.

    Article  Google Scholar 

  7. Kaplan MM, Knox TA, Arora SA. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann Intern Med. 1988;109:429–431.

    CAS  PubMed  Google Scholar 

  8. Kaplan M, DeLellis R, Wolfe H. Sustained biochemical and histological remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997;126:682–688.

    CAS  PubMed  Google Scholar 

  9. Bonis PA, Kaplan MM. The effects of colchicine and methotrexate are additive to ursodeoxycholic acid for patients with primary biliary cirrhosis (PBC) who have responded incompletely to ursodeoxycholic acid. Hepatology. 1997;26:438A.

    Article  Google Scholar 

  10. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005;42:1184–1193.

    Article  CAS  PubMed  Google Scholar 

  11. Hendrickse M, Rigney E, Giaffer M, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology. 1999;117:400–407.

    Article  CAS  PubMed  Google Scholar 

  12. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology. 2004;39:915–923.

    Article  CAS  PubMed  Google Scholar 

  13. Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2005;Jul 20;(3):CD004385, PMID: 16034929.

  14. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;122:652–658.

    Article  CAS  PubMed  Google Scholar 

  15. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med. 2007;357:1524–1529.

    Article  CAS  PubMed  Google Scholar 

  16. Kaplan MM, Gershwin EM. Primary biliary cirrhosis. N Eng J Med. 2005;353:1261–1273.

    Article  CAS  Google Scholar 

  17. Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Dig Dis Sci. 1995;40:1232–1242.

    Article  CAS  PubMed  Google Scholar 

  18. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85–90.

    Article  PubMed  Google Scholar 

  19. Kaplan M, Schmid C, McKusick A, Provenzale D, Sharma A, Sepe T. Double-blind trial of methotrexate (MTX) versus colchicine (COLCH) in primary biliary cirrhosis. Hepatology. 1993;18:176A.

    Google Scholar 

  20. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome; clinical features and response to therapy. Hepatology. 1998;28:296–301.

    Article  CAS  PubMed  Google Scholar 

  21. Novak K, Swain MG. Role of methotrexate in the treatment of chronic cholestatic disorders. Clin Liver Dis. 2008;12:81–96. (viii).

    Article  PubMed  Google Scholar 

  22. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877.

    Article  CAS  PubMed  Google Scholar 

  23. Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther. 2006;24:813–820.

    Article  CAS  PubMed  Google Scholar 

  24. Bonis PAL, Kaplan M. Methotrexate in primary biliary cirrhosis unresponsive to ursodeoxycholic acid: an observational study in 10 patients. Gastroenterology. 1999;117:395–399.

    Article  CAS  PubMed  Google Scholar 

  25. Bonis PA, Kaplan M. Methotrexate for treatment of primary biliary cirrhosis. Hepatology. 2006;43:632. (author reply 632–633).

    Article  PubMed  Google Scholar 

  26. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A. 1977;85:511–518.

    CAS  PubMed  Google Scholar 

  27. Roenigk HJ, Auerbach R, Maibach H, Weinstein G. Methotrexate guidelines–revised. J Am Acad Dermatol. 1982;6:145–155.

    Article  PubMed  Google Scholar 

  28. Zachariae H, Kragballe K, Søgaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol. 1980;102:407–412.

    Article  CAS  PubMed  Google Scholar 

  29. Yazici Y, Erkan D, Harrison M, Nikolov N, Paget SA. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol. 2005;23:517–520.

    CAS  PubMed  Google Scholar 

  30. Menter A, Korman N, Elmets C, Feldman S, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–485.

    Article  CAS  PubMed  Google Scholar 

  31. Saag K, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis J, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;15:762–784.

    Article  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Tufts Medical Center, 800 Washington Street, Boston, MA, 02111, USA

    Marshall M. Kaplan, Alan Bonder & Peter A. L. Bonis

  2. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

    Robin Ruthazer & Peter A. L. Bonis

Authors
  1. Marshall M. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Bonder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robin Ruthazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter A. L. Bonis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marshall M. Kaplan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplan, M.M., Bonder, A., Ruthazer, R. et al. Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid. Dig Dis Sci 55, 3207–3217 (2010). https://doi.org/10.1007/s10620-010-1291-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1291-5

Keywords

Search

Navigation